Response to Comments: MolDX: BRCA1 and BRCA2 Genetic Testing

This document is a response-to-comments notice for the MolDX BRCA1 and BRCA2 genetic testing policy. The public comment period ran 2015-10-13 to 2015-11-27, the notice period ran 2015-12-31 to 2016-02-14, and the LCD was finalized on 2016-02-15. No clinical coverage criteria, limitations, frequency limits, or required clinical documentation were provided in the text supplied.

"Comment period for the draft policy ran from 2015-10-13 to 2015-11-27 during which provider comments were received."

Sign up to see full coverage criteria, indications, and limitations.